Dual FKRP/FST gene therapy normalizes ambulation, increases strength, decreases pathology, and amplifies gene expression in LGMDR9 mice.

MLA

Lam, Patricia, et al. “Dual FKRP/FST Gene Therapy Normalizes Ambulation, Increases Strength, Decreases Pathology, and Amplifies Gene Expression in LGMDR9 Mice.” Molecular Therapy : The Journal of the American Society of Gene Therapy, vol. 32, no. 8, Aug. 2024, pp. 2604–23. EBSCOhost, https://doi.org/10.1016/j.ymthe.2024.06.028.

APA

Lam, P., Zygmunt, D. A., Ashbrook, A., Bennett, M., Vetter, T. A., & Martin, P. T. (2024). Dual FKRP/FST gene therapy normalizes ambulation, increases strength, decreases pathology, and amplifies gene expression in LGMDR9 mice. Molecular Therapy : The Journal of the American Society of Gene Therapy, 32(8), 2604–2623. https://doi.org/10.1016/j.ymthe.2024.06.028

Chicago

Lam, Patricia, Deborah A Zygmunt, Anna Ashbrook, Macey Bennett, Tatyana A Vetter, and Paul T Martin. 2024. “Dual FKRP/FST Gene Therapy Normalizes Ambulation, Increases Strength, Decreases Pathology, and Amplifies Gene Expression in LGMDR9 Mice.” Molecular Therapy : The Journal of the American Society of Gene Therapy 32 (8): 2604–23. doi:10.1016/j.ymthe.2024.06.028.